Alper Topal, Medical Oncologist in the Turkish Armed Forces, shared a post on X about a paper he co-authored with colleagues published in Medicina MDPI:
“We are pleased to announce that our study examining the efficacy and safety profile of crizotinib treatment in patients with metastatic non-small cell lung cancer with ROS1 rearrangement was recently published in Medicina MDPI.
43 patients were included in the study.
- mPFS was 20.9 months.
- mOS was 52.7 months.
- ORR: %72.1, DCR: %79
Our results were similar to PROFILE 1001 trial, with a better side effect profile.”
Authors: Alper Topal, Goncagul Akdag, Sedat Yildirim, Oguzcan Kinikoglu, Deniz Isik, … Mustafa Erman, Hatice Odabas, Nedim Turan, Nuri Karadurmus.
